Drug development

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

Retrieved on: 
Tuesday, March 12, 2024
Infection, Risk, Pharming, United Nations, Manuscript, Weapon, Outline of health sciences, TSX, Therapy, Siege, Drug development, Literature, Safety, Frontiers, Tularemia, FDA, Physician, Vaccine

Appili’s Director of Non-Clinical Research, Dr. Carl Gelhaus, Ph.D., together with medical doctors from the United States Uniformed Services University of the Health Sciences and Ukrainian researchers published a perspective manuscript “ Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement ”.

Key Points: 
  • Appili’s Director of Non-Clinical Research, Dr. Carl Gelhaus, Ph.D., together with medical doctors from the United States Uniformed Services University of the Health Sciences and Ukrainian researchers published a perspective manuscript “ Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement ”.
  • “Appili has been developing ATI-1701 , a biodefense vaccine, to protect warfighters from tularemia.” said Carl Gelhaus, Ph.D., Director of Non-Clinical Research of Appili Therapeutics.
  • “With the help of our Ukrainian colleagues and U.S. Army physicians, we have assessed the potential risk for tularemia outbreaks in Ukraine, by reviewing the literature of previous wartime outbreaks in Eastern Europe.
  • Many of the conditions for tularemia outbreaks now exist in Ukraine, and their warfighters need protection.

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, March 12, 2024
Primary sclerosing cholangitis, Patient, PSC, Integrin, IPF, Idiopathic pulmonary fibrosis, European, Therapy, Drug development, Clutch (eggs), Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis (IPF). The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial. Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).

Key Points: 
  • The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial.
  • Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).
  • “The implementation of BEACON-IPF as an accelerated pivotal, adaptive Phase 2b/3 trial design is another example of our efficient approach to drug development,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics.
  • This facility, along with the Company’s December 31, 2023 cash and cash equivalents of $495.7 million are expected to fund Pliant through 2026.

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
ODD, Research, NF2, RAF, RAS, Patient, Acquisition, Mesothelioma, Drug development, EHE, FDA, Food, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points: 
  • Closed 2023 in a strong financial position with $175M; runway into 2H 2026
    BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023.
  • Collaboration revenue for the three and twelve months ended December 31, 2023 was $0.7 million and $9.2 million, respectively.
  • Research and development expenses for the three and twelve months ended December 31, 2023 were $14.3 million and $59.7 million, respectively.
  • General and administrative for the three and twelve months ended December 31, 2023 were $8.3 million and $24.9 million, respectively.

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

Retrieved on: 
Tuesday, March 12, 2024
Absorption, Obesity, Diabetes, Human, Patient, Gastrointestinal tract, AREC, Semaglutide, Drug development, TRX, AIM, Peptide, Vaccine

Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.

Key Points: 
  • Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.
  • Using TRx Biosciences’ LipiCore™ oral delivery technology alongside Arecor’s formulation platform, Arestat™, the companies intend to jointly develop an oral GLP-1 receptor agonist product with enhanced physicochemical properties that can achieve higher oral bioavailability and stability.
  • Alongside TRx Biosciences and its expertise in targeted oral drug delivery, we have an opportunity to develop an enhanced oral GLP-1 receptor agonist product.
  • Success with semaglutide may offer a path to multiple oral peptide products with enhanced absorption and efficacy.”
    The collaboration provides scope for expansion, following the initial oral GLP-1 receptor agonist programme, to develop further oral peptide products.

Drug Discovery and Early Development Outsourcing Services Industry Analysis - M&As, Partnerships and the Shift Toward an End-to-end CRDMO Model will Boost Sector Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, ChromeOS, ROI, Growth, Neurology, PROTAC, Drug discovery, Partnership, COVID-19, HTS, NGS, RNA, Artificial intelligence, Overalls, Drug development, Machine learning, Fine chemical

The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Drug Discovery and Early Development Outsourcing Services" report has been added to ResearchAndMarkets.com's offering.
  • Overall R&D expenditure totals about $276.81 billion, with a slow 2.5% growth between 2023 to 2024.
  • This activity is improving the partnership landscape across the global drug discovery and preclinical development industry.
  • Last, the larger CROs have developed separate lab testing divisions that allow them to focus on specific drug discovery and preclinical development testing services.

Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Artificial Intelligence, Genetics, Science, Diagnosis, Lung cancer, Algorithm, Immunotherapy, Patient, 2.0, University of Queensland, Biomarker, Tumor microenvironment, Marie Cassidy, Cancer, University, AI, Doctor of Philosophy, Medicine, AACR, Neoplasm, Drug development, Pathology, Therapy, Translational medicine, H&E, Medical imaging

Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.

Key Points: 
  • Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.
  • Leveraging Nucleai's unique AI spatial biology solution, the research uncovered the correlation between the metabolic state and spatial distribution of tumor and immune cells in the tumor microenvironment, shedding new light on treatment outcomes and potential resistance mechanisms.
  • Nucleai is driving innovation in cancer research and collaborating with leading scientists to translate these findings into tangible benefits for patients and healthcare providers worldwide.
  • By integrating spatial biology with AI, Nucleai creates actionable insights from complex pathology data, setting a new standard for diagnosis and treatment, and advancing precision medicine.

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, UBE2M, Oak Ridge National Laboratory, Neurology, Prostate cancer, Serum, FLNA, Drug discovery, Patient, GBM, Hospital, Research, Cancer, University, Hope, Deep learning, AACR, Clinical trial, Drug development, University of Tennessee, Immune system, Stanford University, Multimedia, Netherlands Architecture Institute

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.

Key Points: 
  • BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.
  • The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240405006693/en/
    A graphical representation of BPGbio's NAi Interrogative Biology Platform (Graphic: Business Wire)
    New data further validating the mitochondrial-centric effect of BPM31510 on the immune system.

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

Retrieved on: 
Thursday, April 4, 2024
Data Management, Technology, Pharmaceutical, Professional Services, Biometrics, Medical Devices, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, MSD, American City Business Journals, Growth, AstraZeneca, Data science, Novartis, Patient, Roche, MMS, RWD, AI, Statistics, Data management, Drug development, NCE, FSP, Zee, Fine chemical

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.

Key Points: 
  • MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.
  • Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, including AstraZeneca, MSD, Novartis, Roche, and others.
  • With extended drug development experience, Zee helps to guide the statistical programming team at MMS to support some of the timely execution and evolving regulations for the development of NCEs.
  • Since 2020, the global biometrics CRO has experienced 133 percent growth in Europe.

Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Markets

Retrieved on: 
Thursday, April 4, 2024
Health, Hospitals, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PCR, Mutation, B cell, DNA, BioLegend, Medicine, Cancer, Hospital, Drug development, Bone marrow, Mission, AOCS, Pathology, Vaccine

Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.

Key Points: 
  • Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.
  • Combining multiple samples into a single experiment will help lower this barrier to entry for academic researchers and de-risk the adoption for biopharma.
  • Sample multiplexing by genotyping, unique to Tapestri, uses the genetic information of the relevant variants obtained by bulk next-generation sequencing to distinguish samples.
  • Mission Bio’s multiplexing capabilities make single-cell technology more accessible to the biomedical community and has the potential to dramatically impact patient care in the future.”
    For more information about Tapestri, please visit www.missionbio.com .

Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Data Management, Science, Artificial Intelligence, Principal, Hospice, Drug discovery, Intelligence, Patient, Software, Health policy, Duke Cancer Institute, Drug development, Machine learning, FDA, Medical device

insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors.

Key Points: 
  • insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors.
  • In that role, Dr. Abernethy oversaw the FDA’s vision and execution on the use of data and technology in clinical development.
  • There, she led teams in the development and delivery of software and data products that bridge the gap between clinical research and care.
  • “Amy has a career-long track record of leading high-impact initiatives that leverage clinical data to enable research and development, and accelerate the path of bringing medicines to patients,” said Daphne Koller, Ph.D., CEO and founder of insitro.